Copyright Reports & Markets. All rights reserved.

Global Late Stage Chronic Kidney Disease Drugs Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Late Stage Chronic Kidney Disease Drugs Market Overview

    • 1.1 Product Overview and Scope of Late Stage Chronic Kidney Disease Drugs
    • 1.2 Classification of Late Stage Chronic Kidney Disease Drugs by Types
      • 1.2.1 Global Late Stage Chronic Kidney Disease Drugs Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Types in 2018
      • 1.2.3 Calcimimetics
      • 1.2.4 Vitamin D Sterols
      • 1.2.5 Potassium Binders
      • 1.2.6 Others
    • 1.3 Global Late Stage Chronic Kidney Disease Drugs Market by Application
      • 1.3.1 Global Late Stage Chronic Kidney Disease Drugs Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Hospital Pharmacies
      • 1.3.3 Online Pharnacies
      • 1.3.4 Retail Pharmacies
    • 1.4 Global Late Stage Chronic Kidney Disease Drugs Market by Regions
      • 1.4.1 Global Late Stage Chronic Kidney Disease Drugs Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Late Stage Chronic Kidney Disease Drugs Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Late Stage Chronic Kidney Disease Drugs Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Late Stage Chronic Kidney Disease Drugs Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Late Stage Chronic Kidney Disease Drugs Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Late Stage Chronic Kidney Disease Drugs Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Late Stage Chronic Kidney Disease Drugs (2014-2024)

    2 Company Profiles

    • 2.1 AbbVie
      • 2.1.1 Business Overview
      • 2.1.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 OPKO Health
      • 2.2.1 Business Overview
      • 2.2.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 AstraZeneca
      • 2.3.1 Business Overview
      • 2.3.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Amgen
      • 2.4.1 Business Overview
      • 2.4.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Amgen Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Kyowa Hakko Kirin
      • 2.5.1 Business Overview
      • 2.5.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Ardelyx
      • 2.6.1 Business Overview
      • 2.6.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Sanofi
      • 2.7.1 Business Overview
      • 2.7.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Sanofi Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Akebia Therapeutics
      • 2.8.1 Business Overview
      • 2.8.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Deltanoid
      • 2.9.1 Business Overview
      • 2.9.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Vifor Pharma
      • 2.10.1 Business Overview
      • 2.10.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Shield Therapeutics
      • 2.11.1 Business Overview
      • 2.11.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 ZS Pharma
      • 2.12.1 Business Overview
      • 2.12.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Shire
      • 2.13.1 Business Overview
      • 2.13.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Shire Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Spectrum
      • 2.14.1 Business Overview
      • 2.14.2 Late Stage Chronic Kidney Disease Drugs Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Spectrum Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Late Stage Chronic Kidney Disease Drugs Market Competition, by Players

    • 3.1 Global Late Stage Chronic Kidney Disease Drugs Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Late Stage Chronic Kidney Disease Drugs Players Market Share
      • 3.2.2 Top 10 Late Stage Chronic Kidney Disease Drugs Players Market Share
    • 3.3 Market Competition Trend

    4 Global Late Stage Chronic Kidney Disease Drugs Market Size by Regions

    • 4.1 Global Late Stage Chronic Kidney Disease Drugs Revenue and Market Share by Regions
    • 4.2 North America Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 4.5 South America Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)

    5 North America Late Stage Chronic Kidney Disease Drugs Revenue by Countries

    • 5.1 North America Late Stage Chronic Kidney Disease Drugs Revenue by Countries (2014-2019)
    • 5.2 USA Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)

    6 Europe Late Stage Chronic Kidney Disease Drugs Revenue by Countries

    • 6.1 Europe Late Stage Chronic Kidney Disease Drugs Revenue by Countries (2014-2019)
    • 6.2 Germany Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 6.3 UK Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 6.4 France Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Countries

    • 7.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Countries (2014-2019)
    • 7.2 China Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 7.5 India Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)

    8 South America Late Stage Chronic Kidney Disease Drugs Revenue by Countries

    • 8.1 South America Late Stage Chronic Kidney Disease Drugs Revenue by Countries (2014-2019)
    • 8.2 Brazil Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Late Stage Chronic Kidney Disease Drugs by Countries

    • 9.1 Middle East and Africa Late Stage Chronic Kidney Disease Drugs Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2014-2019)

    10 Global Late Stage Chronic Kidney Disease Drugs Market Segment by Type

    • 10.1 Global Late Stage Chronic Kidney Disease Drugs Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Late Stage Chronic Kidney Disease Drugs Market Forecast by Type (2019-2024)
    • 10.3 Calcimimetics Revenue Growth Rate (2014-2024)
    • 10.4 Vitamin D Sterols Revenue Growth Rate (2014-2024)
    • 10.5 Potassium Binders Revenue Growth Rate (2014-2024)
    • 10.6 Others Revenue Growth Rate (2014-2024)

    11 Global Late Stage Chronic Kidney Disease Drugs Market Segment by Application

    • 11.1 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Application (2014-2019)
    • 11.2 Late Stage Chronic Kidney Disease Drugs Market Forecast by Application (2019-2024)
    • 11.3 Hospital Pharmacies Revenue Growth (2014-2019)
    • 11.4 Online Pharnacies Revenue Growth (2014-2019)
    • 11.5 Retail Pharmacies Revenue Growth (2014-2019)

    12 Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast (2019-2024)

    • 12.1 Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast (2019-2024)
    • 12.2 Global Late Stage Chronic Kidney Disease Drugs Market Forecast by Regions (2019-2024)
    • 12.3 North America Late Stage Chronic Kidney Disease Drugs Revenue Market Forecast (2019-2024)
    • 12.4 Europe Late Stage Chronic Kidney Disease Drugs Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue Market Forecast (2019-2024)
    • 12.6 South America Late Stage Chronic Kidney Disease Drugs Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Late Stage Chronic Kidney Disease Drugs Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Description

      Scope of the Report:
      The global Late Stage Chronic Kidney Disease Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Late Stage Chronic Kidney Disease Drugs.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Late Stage Chronic Kidney Disease Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Late Stage Chronic Kidney Disease Drugs market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      AbbVie
      OPKO Health
      AstraZeneca
      Amgen
      Kyowa Hakko Kirin
      Ardelyx
      Sanofi
      Akebia Therapeutics
      Deltanoid
      Vifor Pharma
      Shield Therapeutics
      ZS Pharma
      Shire
      Spectrum

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Calcimimetics
      Vitamin D Sterols
      Potassium Binders
      Others

      Market Segment by Applications, can be divided into
      Hospital Pharmacies
      Online Pharnacies
      Retail Pharmacies
      Buy now